BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DS-3939a readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of DS-3939a\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05875168-7685@assetmemo.bio
DTSTAMP:20261121T005440Z
DTSTART;VALUE=DATE:20280811
DTEND;VALUE=DATE:20280812
SUMMARY:DS-3939a: Phase 1/2 readout est. (NCT05875168)
DESCRIPTION:DS-3939a\, phase 1/2.\nStudy: First-in-Human Study of DS-3939a 
 in Participants With Advanced Solid Tumors\nEstimated primary completion: 
 11 August 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ds-39
 39a#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05875168
URL:https://assetmemo.bio/drug/ds-3939a#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07739966-7685@assetmemo.bio
DTSTAMP:20261121T005440Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:DS-3939a: Phase 1/2 readout est. (NCT07739966)
DESCRIPTION:DS-3939a\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy of DS-3939a in Participants With Solid Tumors\nEstimated primary compl
 etion: 31 July 2030. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 ds-3939a#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07739966
URL:https://assetmemo.bio/drug/ds-3939a#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
